Intervention Protocol

Lamivudine during pregnancy for preventing hepatitis B virus infection in newborns

  1. Khalid Mumtaz1,*,
  2. Umair Syed Ahmed2,
  3. Nadeem F Zuberi3,
  4. Sumaira Salamat2,
  5. Wasim Jafri2

Editorial Group: Cochrane Hepato-Biliary Group

Published Online: 8 SEP 2010

Assessed as up-to-date: 18 JUL 2010

DOI: 10.1002/14651858.CD008718


How to Cite

Mumtaz K, Ahmed US, Zuberi NF, Salamat S, Jafri W. Lamivudine during pregnancy for preventing hepatitis B virus infection in newborns (Protocol). Cochrane Database of Systematic Reviews 2010, Issue 9. Art. No.: CD008718. DOI: 10.1002/14651858.CD008718.

Author Information

  1. 1

    The Aga Khan University Hospital, Department of Medicine, Karachi, Pakistan

  2. 2

    Aga Khan University Hospital, Department of Medicine, Karachi, Pakistan

  3. 3

    The Aga Khan University Hospital, Department of Paediatrics & Child Health, Karachi, Pakistan

*Khalid Mumtaz, Department of Medicine, The Aga Khan University Hospital, Stadium Road, P.O. Box 74800, Karachi, Pakistan. khalid.mumtaz@aku.edu. drkmumtaz@yahoo.com.

Publication History

  1. Publication Status: New
  2. Published Online: 8 SEP 2010

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To systematically evaluate the benefits and harms of lamivudine in preventing vertical transmission of hepatitis B infection from mother to newborn during pregnancy.